EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Part one of a three-part series.
The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
FDA Slaps Clinical Hold On Miromatrix’s For Bioengineered Liver Platform
The FDA has placed a clinical hold on Miromatrix Medical Inc’s (NASDAQ:MIRO) miroliverELAP Investigational New Drug (IND) application for acute liver failure.…
Xeris Biopharma Announces Plans For A Phase II Dose-Finding Study For Its Investigational Subcutaneous Levothyroxine As Replacement Therapy For Hypothyroidism
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
Third Harmonic Bio Announces Discontinuation Of Phase 1b Study Of THB001 In Chronic Inducible Urticaria
-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID
-- Evidence of clinical activity observed; full data set to be presented at
CASI Pharmaceuticals’ Partner Juventas Announces New Drug Application For CNCT19 Accepted By China National Medical Products Administration
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that China National Medical
ASLAN Pharmaceuticals Announces First Patient Screened In Study Of Eblasakimab In Dupilumab Experienced Atopic Dermatitis Patients
The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment options
The study will enroll 75
Medtronic Announces First Patient Enrolled In U.S. Clinical Trial For Hugo Robotic-assisted Surgery System
Medtronic plc (NYSE:MDT), a global healthcare technology leader, today announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo™ robotic-assisted surgery (RAS) system. The
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc’s (NYSE:MRK) supplemental marketing…
Astria Therapeutics Announces Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 In Healthy Subjects
-- Shown Early Proof of Concept of STAR-0215's Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of Up to 110 Days --
-- Plans to Initiate ALPHA-STAR Phase 1b/2 Trial in Hereditary
AstraZeneca, Merck Provided Update on US Regulatory Priority Review of Lynparza in Combination With Abiraterone in Metastatic Castration-resistant Prostate Cancer
AstraZeneca and MSD today announced that the US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date by three months to provide further time for a full review of the supplementary new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of metastati